Briacell Therapeutics Corp (BCTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.28 (+1.42%), Market cap $0.03B, 52-week low–high $0.63 ~ $13.79.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with
Financial statements, price targets, institutional (13F) holdings and related news for Briacell Therapeutics Corp are updated in real time on BlackAll Trade.
Briacell Therapeutics Corp trades at $4.28 (+1.42%). Real-time quotes and charts are available on BlackAll Trade.
Briacell Therapeutics Corp has a market cap of about $0.03B.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunothe